CanSino Biologics Inc. (688185.SH): Some controlling shareholders collectively used approximately 5.6705 million Hong Kong dollars to increase their Shareholding by 0.278 million shares Listed in Hong Kong.

Gelonghui reported on December 20 that CanSino Biologics Inc. (688185.SH) announced the receipt of a notification letter regarding the completion of the shareholding plan from certain controlling shareholders, XUEFENGYU (Yu Xuefeng), Zhu Tao, SHOUBAICHAO (Chao Shoubai), as well as Executive Director and senior management personnel Wang Jing. During the implementation period of this shareholding plan, based on their determination of the securities market, arrangements for funding the shareholding, and the shareholding window period, XUEFENGYU (Yu Xuefeng), Zhu Tao, and SHOUBAICHAO (Chao Shoubai) each increased their holdings in the company by 100,000 shares and 110,000 shares respectively.

Gelonghui FinanceDec 20 04:35 ET

CanSino Biologics Inc. (688185.SH): The phase I/II clinical trial of the restructured polio vaccine has started in Indonesia and the first subject has been enrolled in phase I clinical trial.

On December 20, Gelonghui reported that CanSino Biologics Inc. (688185.SH) announced the initiation of phase I/II clinical trials for its developed recombinant poliovirus vaccine in Indonesia, successfully enrolling the first subject in phase I. The company's recombinant poliovirus vaccine, based on virus-like particles (VLP), is developed using the company’s protein structure design and VLP assembly technology. It is a non-infectious poliovirus vaccine that does not rely on live viruses during production, and it is expected to have good safety and immunogenicity. The non-infectious VLP technical route for poliovirus.

Gelonghui FinanceDec 20 04:30 ET

Notice highlights | China Eastern Airlines Corporation's passenger traffic increased by about 20% in November; CTIHK expects an annual Net income growth of no less than 30%.

In November, CHINA SOUTH AIR's passenger capacity input rose by 7.18% year-on-year; passenger turnover increased by 15.17% year-on-year; China Eastern Airlines' passenger capacity input increased by 9.19% year-on-year; passenger turnover increased by 20.86% year-on-year.

cls.cnDec 16 19:17 ET

CanSino Biologics' NDA for Combined Vaccine Accepted in China

MT NewswiresDec 16 06:50 ET

CANSINOBIO (06185.HK): The new drug application for DTcP for infants has been accepted.

On December 16, Gelonghui reported that CANSINOBIO (06185.HK) announced that the new drug application for the acellular combined diphtheria, tetanus, and whooping cough vaccine (DTcP) for infants (under 2 years old) has recently received the acceptance notification from the National Medical Products Administration of China. Currently, the manufacturing process of the domestically available purified diphtheria, tetanus, and whooping cough vaccine uses a process of co-purification with the whooping cough antigen, while the infant DTcP developed by the company is a component vaccine for diphtheria, tetanus, and whooping cough, where each whooping cough antigen can be purified separately and formulated in a specified ratio, ensuring product quality between batches.

Gelonghui FinanceDec 16 05:02 ET

Express News | CanSino Biologics Inc - Acceptance of New Drug Application for Dtcp Infant by Nmpa

ReutersDec 16 04:58 ET